Doug Schenkel

“Under your leadership, there are many examples of how Thermo plays offense when others are playing defense, especially in periods of slower growth. Clario and Solventum, those deals in the Sanofi site acquisition.”

“I'll keep them to two and they're both financial. So first on gross margin, you had a really nice quarter, even normalized for catch-ups. You bumped up full year guidance by about a point.”

“One, would you be willing to disaggregate GLP-1 versus non-GLP-1 growth within Q1 HVS. Second, inflationary pressures have intensified, including input and freight costs.”

“I want to follow up on one of Tyco's questions. In Q2, the year-over-year comparison is the most favorable of the year. In previous conversations with you, we got the sense that you were expecting better, than low single digit to mid single digit organic growth.”